First Coronavirus Test with Results Read Directly from a TEST CARD Receives FDA Approval

The United States Food and Drug Administration (FDA) granted emergency use "authorization" for the first antigen test whose results can be read directly from a test card, a design similar to some pregnancy tests. This simple design is fast and effective for healthcare workers and patients and requires no intermediate device for analysis.
An FDA official made the following statement about this new test: “This new COVID-19 antigen test is an important addition to the available tests because results can be read from the test card within minutes. This means people will know almost in real time whether they have the virus. With its simpler design and the large number of tests the company plans to make in the coming months, this new antigen test is an important advance in our fight against the pandemic."
- Related topic: How Is a Coronavirus Test Performed? What Are the Types of PCR and Rapid Diagnostic Tests?
How does the new coronavirus card test work?
A healthcare worker takes a sample from the patient's nose using an instrument similar to a cotton swab and rotates it on a test card containing a test reagent. After waiting 15 minutes, the healthcare worker reads the results directly from the test card. One line indicates a negative result; two lines indicate a positive result.

When should it be preferred?
This test can be used in settings such as a doctor's office, emergency department or some schools. It is authorized for use by a healthcare worker following the onset of coronavirus-related symptoms within seven days in patients suspected of having COVID-19. Given the test's simple nature, card tests are likely to become widely accessible. According to test manufacturer Abbott, it plans to prepare up to 50 million tests per month in the United States by the beginning of October 2020.
Test details
In general, antigen tests are highly specific, meaning they are very successful at "correctly" detecting the novel coronavirus (SARS-CoV-2). However, they are not as sensitive as molecular tests (PCR), meaning that people who are actually ill may receive false-negative results. Because of potentially reduced sensitivity compared with molecular tests, negative antigen test results may need confirmation with a molecular test before treatment decisions are made. Negative antigen test results should be considered in the context of clinical observations and information such as patient history.
Was this article helpful?
Your feedback helps us improve our content.





Reader comments
Share your comment
Your name and comment are published only after administrator approval. Your email address is never shown to visitors.
Be the first to comment.